Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : BioCryst Pharmaceuticals
Deal Size : $264.0 million
Deal Type : Divestment
BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed
Details : Under the agreement, BioCryst sell will its European Orladeyo (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, business to Neopharmed Gentili.
Product Name : Orladeyo
Product Type : Other Small Molecule
Upfront Cash : $250.0 million
June 27, 2025
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : BioCryst Pharmaceuticals
Deal Size : $264.0 million
Deal Type : Divestment